| Scrip Code | 539523 |
|---|---|
| NSE Symbol | ALKEM |
| MSEI Symbol | NOTLISTED |
| ISIN | INE540L01014 |
| Name of company | ALKEM LABORATORIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 14-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | The Company is exclusively engaged in pharmaceutical business |
| Start date and time of board meeting | 14-08-2026 11:00:00 |
| End date and time of board meeting | 14-08-2026 13:40:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 3,74,015.00 | 3,74,015.00 | |
| Other income | 15,275.00 | 15,275.00 | |
| Total income | 3,89,290.00 | 3,89,290.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 91,002.00 | 91,002.00 |
| (b) | Purchases of stock-in-trade | 36,599.00 | 36,599.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (7,474.00) | (7,474.00) |
| (d) | Employee benefit expense | 80,890.00 | 80,890.00 |
| (e) | Finance costs | 4,662.00 | 4,662.00 |
| (f) | Depreciation, depletion and amortisation expense | 10,019.00 | 10,019.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 96,393.00 | 96,393.00 |
| Total other expenses | 96,393.00 | 96,393.00 | |
| Total expenses | 3,12,091.00 | 3,12,091.00 | |
| 3 | Total profit before exceptional items and tax | 77,199.00 | 77,199.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 77,199.00 | 77,199.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 23,206.00 | 23,206.00 |
| 8 | Deferred tax | 1,844.00 | 1,844.00 |
| 9 | Total tax expenses | 25,050.00 | 25,050.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 52,149.00 | 52,149.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | (51.00) | (51.00) |
| 16 | Total profit (loss) for period | 52,098.00 | 52,098.00 |
| 17 | Other comprehensive income net of taxes | 288.00 | 288.00 |
| 18 | Total Comprehensive Income for the period | 52,386.00 | 52,386.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 51,996.00 | 51,996.00 | |
| Total profit or loss, attributable to non-controlling interests | 102.00 | 102.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 52,285.00 | 52,285.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 101.00 | 101.00 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,391.00 | 2,391.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 43.49 | 43.49 | |
| Diluted earnings (loss) per share from continuing operations | 43.49 | 43.49 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 43.49 | 43.49 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 43.49 | 43.49 | |
| 24 | Debt equity ratio | 0 | 0 |
| 25 | Debt service coverage ratio | 0 | 0 |
| 26 | Interest service coverage ratio | 0 | 0 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes to Consolidated financial results: 1) The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2) The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 13 August 2026 and subsequently approved by the Board of Directors at its meeting held on 14 August 2026. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2026. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. 3) Exceptional items includes: 1) During the quarter and year ended 31 March 2026, the Parent Company reviewed its investments in real estate; where recoverability was subject to uncertainties. Accordingly, management reassessed the carrying value of such investments and recognised a provision for impairment amounting to Rs. 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026. 2) During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Parent Company and its Indian subsidiaries assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Parent Company and its Indian subsidiaries have recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs. 602.7 million in the quarter ended 31 March 2026 and Rs. 1,130.6 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. 3) The Group sold its Indore manufactuirng facility in the quarter ended 30 June 2025. The resulting gain amounting to Rs.142.9 million was classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2026 and year ended 31 March 2026. 4) During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate for the quarter and year ended 31 March 2026. Subsequently in the current quarter tax expense has been recognized based on the enacted tax rates applicable under the new regime. 5) The Group, through Alkem Medtech Private Limited, its wholly owned subsidiary, has acquired a majority stake in the equity share capital of Occlutech Holding AG, Switzerland, on 16 July 2026. The acquisition was completed subsequent to the end of the reporting quarter and, accordingly, has no impact on the consolidated financial results for the quarter ended 30 June 2026. 6) The Group operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit or loss | (254.00) | (254.00) |
| Total Amount of items that will not be reclassified to profit and loss | (254.00) | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (84.00) | (84.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified to profit or loss | 458.00 | 458.00 |
| Total Amount of items that will be reclassified to profit and loss | 458.00 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 288.00 | 288.00 |